Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is...
Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance
Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today...
Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return...
The Iran war has reduced the number of new 52-week highs on the NYSE and Nasdaq, and new 52-week lows now dominate across both exchanges. Among the 157 stocks hitting new 52-week lows, three penny stocks...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today...
Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025...
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness,...
Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase...